IV期分化型甲状腺癌术后放射性碘与外照射放疗的生存结局比较
这项回顾性队列研究利用美国国家癌症数据库(NCDB)纳入2002至2012年间接受初次手术的11832例IV期分化型甲状腺癌患者,按组织学与亚分期分层,比较术后放射性碘(RAI)、外照射放疗(EBRT)或无辅助放疗三组的生存结局。结果显示RAI与甲状腺乳头状癌(PTC)和滤泡状甲状腺癌(FTC)各亚分期患者5年和10年生存改善显著相关,而EBRT与若干PTC亚分期更高的死亡风险相关。
要点
- RAI与IV期分化型甲状腺癌各病理亚分期的5年和10年生存改善显著相关。
核心结论
- RAI与IV期分化型甲状腺癌生存改善相关;尽管EBRT有治疗获益,EBRT的治疗指征与晚期DTC尤其是PTC更差的生存结局相关。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库(NCDB),纳入2002至2012年间接受初次手术的11832例IV期分化型甲状腺癌患者。
- 患者按组织学与亚分期分层,比较术后RAI、EBRT或无辅助放疗三组的生存结局。
- 采用全参数多水平生存时间模型评估生存结局,计算未接受放疗患者的风险比(HR)和时间比(TR),所有模型均校正人口学与临床因素。
主要发现
- 全部患者平均年龄61.6岁(SD=11.6),女性占57.5%。
临床怎么用
- 作者认为RAI与IV期分化型甲状腺癌生存改善相关;尽管EBRT有治疗获益,EBRT的治疗指征与晚期DTC尤其是PTC更差的生存结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a lack of well-powered data regarding outcomes in stage IV differentiated thyroid carcinoma (DTC) treated with postsurgical radiation. The objective of this study was to examine survival in patients with stage IV papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) who received radioactive iodine (RAI), external beam radiation therapy (EBRT), or neither following surgery. METHODS: In this retrospective cohort study, data collected from the National Cancer Data Base (NCDB) yielded 11,832 patients with stage IV DTC who underwent primary surgical treatment between 2002 and 2012. Patients were stratified by histology and sub-stage. Fully parametric, multilevel survival-time models were used to evaluate survival outcomes in three adjuvant treatment groups: RAI, EBRT, or no adjuvant radiation. Hazard ratios (HR) and time ratios (TR) were calculated against patients who did not receive radiation. All models were adjusted for demographic and clinical factors. RESULTS: The mean age of all patients was 61.6 years (SD = 11.6), and 57.5% were female. Patients who received EBRT had significantly higher 5- and 10-year hazards of death in several PTC sub-stages (10-year HRPTC Stage IV-A = 2.12 [confidence interval (CI) 1.79-2.52]; HRPTC Stage IV-B = 2.03 [CI 1.33-3.10]). For stage IV-B PTC requiring EBRT, lifespan after diagnosis was shortened by a factor of 3 when compared to patients who did not receive radiation (TRPTC Stage IV-B = 0.32 [CI 0.16-0.62]). In contrast, RAI was significantly associated with improved 5- and 10-year survival in both PTC and FTC patients regardless of pathological sub-stage. Large reductions in mortality were observed in patients with FTC who were treated with RAI (HRFTC Stage IV-C = 0.19 [CI 0.06-0.65]). When patients with stage IV-C FTC were treated with RAI, life-span after diagnosis doubled (TRFTC Stage IV-C = 1.98 [CI 1.31-3.00]). CONCLUSIONS: Through the NCDB, this study sought to describe prognosis and survival for adjuvant radiation in stage IV DTC. RAI was associated with improved survival for stage IV DTC. Despite treatment benefits conferred by adjuvant EBRT, indications to treat with EBRT were associated with poorer survival outcomes in patients with advanced-stage DTC, particularly PTC.
引用
- Yang Z, Flores J, Katz S, et al. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma. Thyroid. 2017. PMID: 28446057. doi:10.1089/thy.2016.0650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。